繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Rafael Holdings to Merge With Cyclo Therapeutics

2024-08-22 19:20

07:20 AM EDT, 08/22/2024 (MT Newswires) -- Rafael Holdings (RFL) has agreed to merge with Cyclo Therapeutics (CYTH), the companies said Thursday.

Under the terms of the deal, Rafael Holdings will issue class B common shares to Cyclo shareholders, on an exchange ratio valuing Cyclo shares at $0.95 per share and Rafael at its cash value combined with the value of its marketable securities and other investments minus liabilities. The cash value will factor in Rafael's funding of Cyclo operations through closing, the companies said.

Both companies' boards have approved the merger, which is expected to close by Q4.

The companies said they will focus on the development of the drug, Trappsol Cyclo, as a potential treatment for Niemann-Pick Disease Type C1, a rare genetic disease.

Shares of Cyclo fell more than 20% in recent pre-bell activity Thursday, while Rafael was inactive.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。